- Home
- CAAS vs SGMT Comparison
CAAS vs SGMT Comparison
Compare CAAS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAS
- SGMT
- Stock Information
- Founded
- CAAS N/A
- SGMT 2006
- Country
- CAAS China
- SGMT United States
- Employees
- CAAS N/A
- SGMT N/A
- Industry
- CAAS Auto Parts:O.E.M.
- SGMT
- Sector
- CAAS Consumer Discretionary
- SGMT
- Exchange
- CAAS Nasdaq
- SGMT Nasdaq
- Market Cap
- CAAS 116.8M
- SGMT 71.2M
- IPO Year
- CAAS N/A
- SGMT 2023
- Fundamental
- Price
- CAAS $4.15
- SGMT $3.20
- Analyst Decision
- CAAS
- SGMT Strong Buy
- Analyst Count
- CAAS 0
- SGMT 6
- Target Price
- CAAS N/A
- SGMT $25.67
- AVG Volume (30 Days)
- CAAS 27.0K
- SGMT 553.0K
- Earning Date
- CAAS 05-14-2025
- SGMT 05-08-2025
- Dividend Yield
- CAAS N/A
- SGMT N/A
- EPS Growth
- CAAS N/A
- SGMT N/A
- EPS
- CAAS 0.99
- SGMT N/A
- Revenue
- CAAS $650,935,000.00
- SGMT N/A
- Revenue This Year
- CAAS N/A
- SGMT N/A
- Revenue Next Year
- CAAS N/A
- SGMT N/A
- P/E Ratio
- CAAS $4.07
- SGMT N/A
- Revenue Growth
- CAAS 12.94
- SGMT N/A
- 52 Week Low
- CAAS $3.34
- SGMT $1.73
- 52 Week High
- CAAS $5.37
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- CAAS 56.50
- SGMT 51.26
- Support Level
- CAAS $3.78
- SGMT $3.24
- Resistance Level
- CAAS $3.93
- SGMT $4.12
- Average True Range (ATR)
- CAAS 0.16
- SGMT 0.33
- MACD
- CAAS 0.06
- SGMT 0.07
- Stochastic Oscillator
- CAAS 91.23
- SGMT 49.73
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.